132 related articles for article (PubMed ID: 19115686)
21. Sample size and power determination when limited preliminary information is available.
McLaren CE; Chen WP; O'Sullivan TD; Gillen DL; Su MY; Chen JH; Tromberg BJ
BMC Med Res Methodol; 2017 Apr; 17(1):75. PubMed ID: 28446127
[TBL] [Abstract][Full Text] [Related]
22. Can mammographic densities predict effects of tamoxifen on the breast?
Ursin G; Pike MC; Spicer DV; Porrath SA; Reitherman RW
J Natl Cancer Inst; 1996 Jan; 88(2):128-9. PubMed ID: 8537975
[No Abstract] [Full Text] [Related]
23. Regression of breast cancer in four patients treated with tamoxifen: mammographic features.
Taylor C; Georgian-Smith D
AJR Am J Roentgenol; 1994 Mar; 162(3):613-6. PubMed ID: 8109507
[TBL] [Abstract][Full Text] [Related]
24. Effect of tamoxifen on breast tissue density in premenopausal breast cancer.
Slanetz PJ; Grandpre LE; Yeh ED; Kopans DB; Mendel JB
Breast J; 2004; 10(1):27-32. PubMed ID: 14717756
[TBL] [Abstract][Full Text] [Related]
25. The relationship of mammographic density and age: implications for breast cancer screening.
Checka CM; Chun JE; Schnabel FR; Lee J; Toth H
AJR Am J Roentgenol; 2012 Mar; 198(3):W292-5. PubMed ID: 22358028
[TBL] [Abstract][Full Text] [Related]
26. Mammographic breast density in infertile and parous women.
Letizia MM; Rita VA; Grazia SM; Valentina C; Filippo B; Diana M; Paola NM; Cesare A; Carlo F
BMC Womens Health; 2016 Feb; 16():8. PubMed ID: 26861058
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of mammographic density change after initiation of tamoxifen for ER-positive breast cancer.
Nyante SJ; Sherman ME; Pfeiffer RM; Berrington de Gonzalez A; Brinton LA; Aiello Bowles EJ; Hoover RN; Glass A; Gierach GL
J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25663687
[TBL] [Abstract][Full Text] [Related]
28. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
[TBL] [Abstract][Full Text] [Related]
29. Second cancers after adjuvant tamoxifen therapy for breast cancer in Japan.
Matsuyama Y; Tominaga T; Nomura Y; Koyama H; Kimura M; Sano M; Miura S; Takashima S; Mitsuyama S; Ueo H; Ohashi Y
Ann Oncol; 2000 Dec; 11(12):1537-43. PubMed ID: 11205460
[TBL] [Abstract][Full Text] [Related]
30. Longitudinal Change in Mammographic Density among ER-Positive Breast Cancer Patients Using Tamoxifen.
Nyante SJ; Sherman ME; Pfeiffer RM; Berrington de Gonzalez A; Brinton LA; Bowles EJ; Hoover RN; Glass A; Gierach GL
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):212-6. PubMed ID: 26545407
[TBL] [Abstract][Full Text] [Related]
31. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
[TBL] [Abstract][Full Text] [Related]
32. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
[TBL] [Abstract][Full Text] [Related]
33. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N
J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118
[TBL] [Abstract][Full Text] [Related]
34. Tamoxifen and mammographic breast densities.
Brisson J; Brisson B; Coté G; Maunsell E; Bérubé S; Robert J
Cancer Epidemiol Biomarkers Prev; 2000 Sep; 9(9):911-5. PubMed ID: 11008908
[TBL] [Abstract][Full Text] [Related]
35. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.
Crivellari D; Bonetti M; Castiglione-Gertsch M; Gelber RD; Rudenstam CM; Thürlimann B; Price KN; Coates AS; Hürny C; Bernhard J; Lindtner J; Collins J; Senn HJ; Cavalli F; Forbes J; Gudgeon A; Simoncini E; Cortes-Funes H; Veronesi A; Fey M; Goldhirsch A
J Clin Oncol; 2000 Apr; 18(7):1412-22. PubMed ID: 10735888
[TBL] [Abstract][Full Text] [Related]
36. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy.
Sverrisdóttir A; Fornander T; Jacobsson H; von Schoultz E; Rutqvist LE
J Clin Oncol; 2004 Sep; 22(18):3694-9. PubMed ID: 15365065
[TBL] [Abstract][Full Text] [Related]
37. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group.
Tormey DC; Gray R; Falkson HC
J Natl Cancer Inst; 1996 Dec; 88(24):1828-33. PubMed ID: 8961972
[TBL] [Abstract][Full Text] [Related]
38. Impact of tamoxifen on amount of fibroglandular tissue, background parenchymal enhancement, and cysts on breast magnetic resonance imaging.
King V; Kaplan J; Pike MC; Liberman L; David Dershaw D; Lee CH; Brooks JD; Morris EA
Breast J; 2012; 18(6):527-34. PubMed ID: 23002953
[TBL] [Abstract][Full Text] [Related]
39. [The effect of long-term tamoxifen therapy on the occurrence of contralateral primary breast cancer].
Xing B; Huang X; Wang Y
Zhonghua Zhong Liu Za Zhi; 1996 Mar; 18(2):143-5. PubMed ID: 9206051
[TBL] [Abstract][Full Text] [Related]
40. Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk.
Spicer DV; Ursin G; Parisky YR; Pearce JG; Shoupe D; Pike A; Pike MC
J Natl Cancer Inst; 1994 Mar; 86(6):431-6. PubMed ID: 8120917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]